To explore the clinical efficacy of atorvastatin calcium combined with ticagrelor in patients with coronary heart disease and hyperlipidemia and its effect on serum cytokines.

139 patients with coronary heart disease and hyperlipidemia who were diagnosed and treated in our hospital from April 2018 to March 2019 were randomly divided into control group and observation group. The control group was treated with atorvastatin calcium combined with clopidogrel. The observation group was given atorvastatin calcium combined with ticagrelor for 12 weeks. The frequency and duration of angina pectoris in the two groups before and after treatment were recorded, and the TC, TG, HDL-C, LDL-C, and Serum Hcy, hs-CRP and VEGF levels were changed, and the adverse reactions of the two groups of patients were observed.

The frequency and duration of angina pectoris in the observation group after 12 weeks of intervention were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the levels of TC, HDL-C, LDL-C, TG and serum Hcy, hs-CRP and VEGF before intervention between the two groups of patients (P>0.05). The TC, HDL-C, LDL-C and TG were significantly improved (P<0.05), the content of Hcy and hs-CRP in the serum was significantly reduced (P<0.05), while the content of VEGF was significantly increased (P<0.05); and compared with the control group Compared with the observation group, the serum Hcy and hs-CRP levels decreased significantly after treatment, while the VEGF level increased significantly, and the difference was statistically significant (P<0.05).

Atorvastatin calcium combined with ticagrelor can effectively control the blood lipid level of patients with coronary heart disease hyperlipidemia, inhibit the content of Hcy and hs-CRP in the serum, and increase the expression level of VEGF. The effect is better than that of atorvastatin calcium. Combined clopidogrel regimen.